Rigel Pharmaceuticals (RIGL) Work In Process (2018 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Work In Process of $6.2 million for Q1 2026, up 462.69% year-over-year from $1.1 million in Q1 2025, and up 59.31% quarter-over-quarter from $3.9 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Work In Process (2018 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Work In Process history runs 9 years deep, the most recent figure standing at $6.2 million for Q1 2026.
- In Q1 2026, Work In Process rose 462.69% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 462.69% YoY), while the FY2025 annual figure was $3.9 million, up 218.92% from the prior year.
- Work In Process for Q1 2026 stood at $6.2 million, up from $3.9 million in the prior quarter.
- The five-year high for Work In Process was $6.2 million in Q1 2026, with the low at $572000.0 in Q2 2022.
- The 5-year median for Work In Process is $2.0 million (2023), against an average of $2.8 million.
- The sharpest annual moves came in 2022 and 2025: Work In Process jumped 1541.36% in 2022, then plunged 78.38% in 2025.
- Rigel Pharmaceuticals' Work In Process stood at $2.7 million in 2022, then dropped by 29.45% to $1.9 million in 2023, then plunged by 34.65% to $1.2 million in 2024, then soared by 218.92% to $3.9 million in 2025, then jumped by 59.31% to $6.2 million in 2026.
- Business Quant data shows RIGL's Work In Process at $6.2 million in Q1 2026, $3.9 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.00 Mn |
| Mar 31, 2026 | 6.23 Mn |
| Dec 31, 2025 | 3.91 Mn |
| Sep 30, 2025 | 5.49 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 6.01 Mn |
| Mar 31, 2024 | 5.12 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Jun 30, 2023 | 2.05 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 2.66 Mn |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 572,000.00 |
| Mar 31, 2022 | 1.04 Mn |
| Dec 31, 2021 | 162,000.00 |
| Sep 30, 2021 | 483,000.00 |
| Jun 30, 2021 | 340,000.00 |